| Title |
Single dose oral celecoxib for acute postoperative pain in adults
|
|---|---|
| Published in |
Cochrane database of systematic reviews, October 2013
|
| DOI | 10.1002/14651858.cd004233.pub4 |
| Pubmed ID | |
| Authors |
Sheena Derry, R Andrew Moore |
| Abstract |
This is an update of a review first published in The Cochrane Library in Issue 4, 2008, and updated in Issue 3, 2012. Celecoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor usually prescribed for the relief of chronic pain in osteoarthritis and rheumatoid arthritis. Celecoxib is believed to be associated with fewer upper gastrointestinal adverse effects than conventional non-steroidal anti-inflammatory drugs (NSAIDs). Its effectiveness in acute pain was demonstrated in the earlier reviews. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 8% |
| United Kingdom | 1 | 8% |
| Peru | 1 | 8% |
| Chile | 1 | 8% |
| Colombia | 1 | 8% |
| Unknown | 7 | 58% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 75% |
| Scientists | 2 | 17% |
| Practitioners (doctors, other healthcare professionals) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 179 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 1% |
| Italy | 1 | <1% |
| Malaysia | 1 | <1% |
| Canada | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 173 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 29 | 16% |
| Other | 19 | 11% |
| Student > Ph. D. Student | 18 | 10% |
| Student > Bachelor | 18 | 10% |
| Researcher | 14 | 8% |
| Other | 38 | 21% |
| Unknown | 43 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 80 | 45% |
| Nursing and Health Professions | 14 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 4% |
| Agricultural and Biological Sciences | 5 | 3% |
| Biochemistry, Genetics and Molecular Biology | 3 | 2% |
| Other | 17 | 9% |
| Unknown | 52 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 September 2022.
All research outputs
#1,684,357
of 23,577,761 outputs
Outputs from Cochrane database of systematic reviews
#3,839
of 12,746 outputs
Outputs of similar age
#16,290
of 213,860 outputs
Outputs of similar age from Cochrane database of systematic reviews
#77
of 212 outputs
Altmetric has tracked 23,577,761 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,746 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.1. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,860 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 212 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.